|
KMID : 0882420190940030294
|
|
Korean Journal of Medicine
2019 Volume.94 No. 3 p.294 ~ p.298
|
|
|
Concurrent, Prolonged Use of Bedaquiline and Delamanid for Multidrug-Resistant Tuberculosis
|
|
Hwangbo Hyun
Lee Se-Hee
Jo Kyung-Uk
Shim Tae-Sun
|
|
|
Abstract
|
|
|
|
Bedaquiline and delamanid were recently approved for the treatment of multidrug-resistant tuberculosis (MDR-TB) in Korea. A treatment duration of 24 weeks was established based on phase 2 clinical trial data, although the combined use of these two drugs is typically not recommended because it may exaggerate QT prolongation. Here, we present a case of prolonged treatment (48 weeks) with a combination of bedaquiline and delamanid for pulmonary MDR-TB. The patient had previously been diagnosed with extensively drug-resistant TB but had been left untreated for the past 9 years due to a shortage of effective drugs. A combination of bedaquiline and delamanid successfully treated MDR-TB, highlighting the potential efficacy of these drugs for patients with drug-resistant TB infections.
|
|
|
KEYWORD
|
|
|
Bedaquiline, Delamanid, Tuberculosis, Multidrug-resistant
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
  
|